nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenazopyridine—SCN7A—prostate gland—urinary bladder cancer	0.053	0.154	CbGeAlD
Phenazopyridine—SCN9A—prostate gland—urinary bladder cancer	0.0415	0.121	CbGeAlD
Phenazopyridine—SCN4A—prostate gland—urinary bladder cancer	0.037	0.108	CbGeAlD
Phenazopyridine—SCN7A—female reproductive system—urinary bladder cancer	0.0289	0.0841	CbGeAlD
Phenazopyridine—SCN3A—prostate gland—urinary bladder cancer	0.0288	0.0838	CbGeAlD
Phenazopyridine—SCN4A—renal system—urinary bladder cancer	0.0252	0.0734	CbGeAlD
Phenazopyridine—SCN3A—renal system—urinary bladder cancer	0.0196	0.0571	CbGeAlD
Phenazopyridine—SCN7A—lymph node—urinary bladder cancer	0.0169	0.0492	CbGeAlD
Phenazopyridine—SCN2A—vagina—urinary bladder cancer	0.0162	0.0471	CbGeAlD
Phenazopyridine—Meningitis aseptic—Methotrexate—urinary bladder cancer	0.0158	0.0727	CcSEcCtD
Phenazopyridine—SCN3A—female reproductive system—urinary bladder cancer	0.0157	0.0457	CbGeAlD
Phenazopyridine—SCN3A—vagina—urinary bladder cancer	0.0142	0.0414	CbGeAlD
Phenazopyridine—SCN5A—vagina—urinary bladder cancer	0.0142	0.0412	CbGeAlD
Phenazopyridine—SCN9A—lymph node—urinary bladder cancer	0.0133	0.0386	CbGeAlD
Phenazopyridine—SCN4A—L1CAM interactions—CNTN2—urinary bladder cancer	0.0121	0.0276	CbGpPWpGaD
Phenazopyridine—SCN1A—L1CAM interactions—CNTN2—urinary bladder cancer	0.0117	0.0266	CbGpPWpGaD
Phenazopyridine—SCN10A—L1CAM interactions—CNTN2—urinary bladder cancer	0.0117	0.0266	CbGpPWpGaD
Phenazopyridine—SCN10A—lymph node—urinary bladder cancer	0.0101	0.0293	CbGeAlD
Phenazopyridine—SCN3A—lymph node—urinary bladder cancer	0.0092	0.0268	CbGeAlD
Phenazopyridine—SCN5A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00819	0.0187	CbGpPWpGaD
Phenazopyridine—SCN7A—Axon guidance—CNTN2—urinary bladder cancer	0.00754	0.0172	CbGpPWpGaD
Phenazopyridine—SCN11A—Axon guidance—CNTN2—urinary bladder cancer	0.00672	0.0153	CbGpPWpGaD
Phenazopyridine—Pruritus—Valrubicin—urinary bladder cancer	0.00631	0.029	CcSEcCtD
Phenazopyridine—SCN8A—Axon guidance—CNTN2—urinary bladder cancer	0.00614	0.014	CbGpPWpGaD
Phenazopyridine—Diarrhoea—Valrubicin—urinary bladder cancer	0.0061	0.028	CcSEcCtD
Phenazopyridine—Vomiting—Valrubicin—urinary bladder cancer	0.00567	0.0261	CcSEcCtD
Phenazopyridine—Rash—Valrubicin—urinary bladder cancer	0.00562	0.0258	CcSEcCtD
Phenazopyridine—Dermatitis—Valrubicin—urinary bladder cancer	0.00562	0.0258	CcSEcCtD
Phenazopyridine—Headache—Valrubicin—urinary bladder cancer	0.00559	0.0257	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.00546	0.0251	CcSEcCtD
Phenazopyridine—SCN7A—Developmental Biology—CNTN2—urinary bladder cancer	0.00538	0.0123	CbGpPWpGaD
Phenazopyridine—Nausea—Valrubicin—urinary bladder cancer	0.0053	0.0243	CcSEcCtD
Phenazopyridine—SCN9A—Axon guidance—CNTN2—urinary bladder cancer	0.00497	0.0113	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—CNTN2—urinary bladder cancer	0.00479	0.0109	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—CNTN2—urinary bladder cancer	0.00475	0.0108	CbGpPWpGaD
Phenazopyridine—Jaundice—Thiotepa—urinary bladder cancer	0.00472	0.0217	CcSEcCtD
Phenazopyridine—SCN4A—Axon guidance—CNTN2—urinary bladder cancer	0.00457	0.0104	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—CNTN2—urinary bladder cancer	0.00457	0.0104	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—CNTN2—urinary bladder cancer	0.0044	0.01	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—CNTN2—urinary bladder cancer	0.0044	0.01	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—CNTN2—urinary bladder cancer	0.00439	0.01	CbGpPWpGaD
Phenazopyridine—Diarrhoea—Mitomycin—urinary bladder cancer	0.0042	0.0193	CcSEcCtD
Phenazopyridine—Vomiting—Mitomycin—urinary bladder cancer	0.00391	0.018	CcSEcCtD
Phenazopyridine—Rash—Mitomycin—urinary bladder cancer	0.00387	0.0178	CcSEcCtD
Phenazopyridine—Dermatitis—Mitomycin—urinary bladder cancer	0.00387	0.0178	CcSEcCtD
Phenazopyridine—Headache—Mitomycin—urinary bladder cancer	0.00385	0.0177	CcSEcCtD
Phenazopyridine—Nausea—Mitomycin—urinary bladder cancer	0.00365	0.0168	CcSEcCtD
Phenazopyridine—SCN9A—Developmental Biology—CNTN2—urinary bladder cancer	0.00355	0.00809	CbGpPWpGaD
Phenazopyridine—SCN7A—L1CAM interactions—SRC—urinary bladder cancer	0.0034	0.00776	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—CNTN2—urinary bladder cancer	0.00339	0.00773	CbGpPWpGaD
Phenazopyridine—Jaundice—Etoposide—urinary bladder cancer	0.00339	0.0156	CcSEcCtD
Phenazopyridine—SCN5A—Cardiac Progenitor Differentiation—IGF1—urinary bladder cancer	0.00335	0.00765	CbGpPWpGaD
Phenazopyridine—Visual impairment—Cisplatin—urinary bladder cancer	0.00329	0.0151	CcSEcCtD
Phenazopyridine—SCN2A—Developmental Biology—CNTN2—urinary bladder cancer	0.00326	0.00743	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—CNTN2—urinary bladder cancer	0.00326	0.00743	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—CNTN2—urinary bladder cancer	0.00314	0.00716	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—CNTN2—urinary bladder cancer	0.00314	0.00716	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—CNTN2—urinary bladder cancer	0.0031	0.00706	CbGpPWpGaD
Phenazopyridine—SCN11A—L1CAM interactions—SRC—urinary bladder cancer	0.00303	0.00692	CbGpPWpGaD
Phenazopyridine—SCN7A—L1CAM interactions—EGFR—urinary bladder cancer	0.00298	0.0068	CbGpPWpGaD
Phenazopyridine—Visual disturbance—Methotrexate—urinary bladder cancer	0.00285	0.0131	CcSEcCtD
Phenazopyridine—SCN8A—L1CAM interactions—SRC—urinary bladder cancer	0.00278	0.00633	CbGpPWpGaD
Phenazopyridine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00272	0.0125	CcSEcCtD
Phenazopyridine—SCN5A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00269	0.00614	CbGpPWpGaD
Phenazopyridine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00267	0.0123	CcSEcCtD
Phenazopyridine—SCN11A—L1CAM interactions—EGFR—urinary bladder cancer	0.00266	0.00606	CbGpPWpGaD
Phenazopyridine—SCN8A—L1CAM interactions—EGFR—urinary bladder cancer	0.00243	0.00555	CbGpPWpGaD
Phenazopyridine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00228	0.0105	CcSEcCtD
Phenazopyridine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00225	0.0103	CcSEcCtD
Phenazopyridine—SCN9A—L1CAM interactions—SRC—urinary bladder cancer	0.00224	0.00512	CbGpPWpGaD
Phenazopyridine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00224	0.0103	CcSEcCtD
Phenazopyridine—SCN5A—Developmental Biology—CNTN2—urinary bladder cancer	0.00221	0.00504	CbGpPWpGaD
Phenazopyridine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00221	0.0101	CcSEcCtD
Phenazopyridine—Pruritus—Thiotepa—urinary bladder cancer	0.00219	0.01	CcSEcCtD
Phenazopyridine—SCN3A—L1CAM interactions—SRC—urinary bladder cancer	0.00215	0.00489	CbGpPWpGaD
Phenazopyridine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00211	0.00972	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00209	0.00961	CcSEcCtD
Phenazopyridine—SCN2A—L1CAM interactions—SRC—urinary bladder cancer	0.00206	0.0047	CbGpPWpGaD
Phenazopyridine—SCN4A—L1CAM interactions—SRC—urinary bladder cancer	0.00206	0.0047	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—NCOR1—urinary bladder cancer	0.00201	0.00459	CbGpPWpGaD
Phenazopyridine—SCN1A—L1CAM interactions—SRC—urinary bladder cancer	0.00199	0.00453	CbGpPWpGaD
Phenazopyridine—SCN10A—L1CAM interactions—SRC—urinary bladder cancer	0.00199	0.00453	CbGpPWpGaD
Phenazopyridine—SCN9A—L1CAM interactions—EGFR—urinary bladder cancer	0.00197	0.00448	CbGpPWpGaD
Phenazopyridine—Vomiting—Thiotepa—urinary bladder cancer	0.00196	0.00903	CcSEcCtD
Phenazopyridine—Rash—Thiotepa—urinary bladder cancer	0.00195	0.00895	CcSEcCtD
Phenazopyridine—Dermatitis—Thiotepa—urinary bladder cancer	0.00195	0.00894	CcSEcCtD
Phenazopyridine—Headache—Thiotepa—urinary bladder cancer	0.00194	0.0089	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00192	0.00881	CcSEcCtD
Phenazopyridine—Jaundice—Epirubicin—urinary bladder cancer	0.0019	0.00874	CcSEcCtD
Phenazopyridine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00188	0.00865	CcSEcCtD
Phenazopyridine—SCN3A—L1CAM interactions—EGFR—urinary bladder cancer	0.00188	0.00429	CbGpPWpGaD
Phenazopyridine—Hepatitis—Methotrexate—urinary bladder cancer	0.00187	0.0086	CcSEcCtD
Phenazopyridine—Pruritus—Gemcitabine—urinary bladder cancer	0.00184	0.00845	CcSEcCtD
Phenazopyridine—Nausea—Thiotepa—urinary bladder cancer	0.00183	0.00843	CcSEcCtD
Phenazopyridine—SCN4A—L1CAM interactions—EGFR—urinary bladder cancer	0.00181	0.00412	CbGpPWpGaD
Phenazopyridine—SCN2A—L1CAM interactions—EGFR—urinary bladder cancer	0.00181	0.00412	CbGpPWpGaD
Phenazopyridine—Pruritus—Fluorouracil—urinary bladder cancer	0.00181	0.00831	CcSEcCtD
Phenazopyridine—Visual impairment—Methotrexate—urinary bladder cancer	0.0018	0.00829	CcSEcCtD
Phenazopyridine—SCN11A—Developmental Biology—NCOR1—urinary bladder cancer	0.00179	0.00409	CbGpPWpGaD
Phenazopyridine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00178	0.0082	CcSEcCtD
Phenazopyridine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00178	0.00817	CcSEcCtD
Phenazopyridine—Jaundice—Doxorubicin—urinary bladder cancer	0.00176	0.00809	CcSEcCtD
Phenazopyridine—SCN7A—Axon guidance—RHOA—urinary bladder cancer	0.00176	0.00401	CbGpPWpGaD
Phenazopyridine—Hepatitis—Epirubicin—urinary bladder cancer	0.00175	0.00805	CcSEcCtD
Phenazopyridine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00175	0.00804	CcSEcCtD
Phenazopyridine—SCN1A—L1CAM interactions—EGFR—urinary bladder cancer	0.00174	0.00397	CbGpPWpGaD
Phenazopyridine—SCN10A—L1CAM interactions—EGFR—urinary bladder cancer	0.00174	0.00397	CbGpPWpGaD
Phenazopyridine—Visual impairment—Epirubicin—urinary bladder cancer	0.00169	0.00776	CcSEcCtD
Phenazopyridine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00166	0.00762	CcSEcCtD
Phenazopyridine—Vomiting—Gemcitabine—urinary bladder cancer	0.00165	0.00759	CcSEcCtD
Phenazopyridine—SCN8A—Developmental Biology—NCOR1—urinary bladder cancer	0.00164	0.00374	CbGpPWpGaD
Phenazopyridine—Rash—Gemcitabine—urinary bladder cancer	0.00164	0.00753	CcSEcCtD
Phenazopyridine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00164	0.00752	CcSEcCtD
Phenazopyridine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00163	0.00751	CcSEcCtD
Phenazopyridine—Headache—Gemcitabine—urinary bladder cancer	0.00163	0.00748	CcSEcCtD
Phenazopyridine—SCN7A—Axon guidance—ERBB2—urinary bladder cancer	0.00163	0.00371	CbGpPWpGaD
Phenazopyridine—Vomiting—Fluorouracil—urinary bladder cancer	0.00162	0.00747	CcSEcCtD
Phenazopyridine—Hepatitis—Doxorubicin—urinary bladder cancer	0.00162	0.00745	CcSEcCtD
Phenazopyridine—Rash—Fluorouracil—urinary bladder cancer	0.00161	0.00741	CcSEcCtD
Phenazopyridine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00161	0.0074	CcSEcCtD
Phenazopyridine—Headache—Fluorouracil—urinary bladder cancer	0.0016	0.00736	CcSEcCtD
Phenazopyridine—SCN7A—Developmental Biology—CDK4—urinary bladder cancer	0.00159	0.00362	CbGpPWpGaD
Phenazopyridine—Pruritus—Etoposide—urinary bladder cancer	0.00157	0.00722	CcSEcCtD
Phenazopyridine—SCN11A—Axon guidance—RHOA—urinary bladder cancer	0.00157	0.00357	CbGpPWpGaD
Phenazopyridine—Visual impairment—Doxorubicin—urinary bladder cancer	0.00156	0.00718	CcSEcCtD
Phenazopyridine—Nausea—Gemcitabine—urinary bladder cancer	0.00154	0.0071	CcSEcCtD
Phenazopyridine—Vomiting—Cisplatin—urinary bladder cancer	0.00154	0.00708	CcSEcCtD
Phenazopyridine—Rash—Cisplatin—urinary bladder cancer	0.00153	0.00702	CcSEcCtD
Phenazopyridine—Dermatitis—Cisplatin—urinary bladder cancer	0.00153	0.00701	CcSEcCtD
Phenazopyridine—Diarrhoea—Etoposide—urinary bladder cancer	0.00152	0.00698	CcSEcCtD
Phenazopyridine—Nausea—Fluorouracil—urinary bladder cancer	0.00152	0.00698	CcSEcCtD
Phenazopyridine—SCN11A—Axon guidance—ERBB2—urinary bladder cancer	0.00145	0.00331	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—PPARG—urinary bladder cancer	0.00144	0.00329	CbGpPWpGaD
Phenazopyridine—Nausea—Cisplatin—urinary bladder cancer	0.00144	0.00661	CcSEcCtD
Phenazopyridine—SCN8A—Axon guidance—RHOA—urinary bladder cancer	0.00143	0.00327	CbGpPWpGaD
Phenazopyridine—SCN5A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.00143	0.00326	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—CDK4—urinary bladder cancer	0.00142	0.00323	CbGpPWpGaD
Phenazopyridine—Vomiting—Etoposide—urinary bladder cancer	0.00141	0.00649	CcSEcCtD
Phenazopyridine—Rash—Etoposide—urinary bladder cancer	0.0014	0.00643	CcSEcCtD
Phenazopyridine—SCN5A—L1CAM interactions—SRC—urinary bladder cancer	0.0014	0.00319	CbGpPWpGaD
Phenazopyridine—Dermatitis—Etoposide—urinary bladder cancer	0.0014	0.00643	CcSEcCtD
Phenazopyridine—SCN7A—Axon guidance—MMP9—urinary bladder cancer	0.0014	0.00318	CbGpPWpGaD
Phenazopyridine—Headache—Etoposide—urinary bladder cancer	0.00139	0.00639	CcSEcCtD
Phenazopyridine—SCN7A—Developmental Biology—CREBBP—urinary bladder cancer	0.00139	0.00316	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—NCOR1—urinary bladder cancer	0.00133	0.00303	CbGpPWpGaD
Phenazopyridine—SCN8A—Axon guidance—ERBB2—urinary bladder cancer	0.00133	0.00302	CbGpPWpGaD
Phenazopyridine—Nausea—Etoposide—urinary bladder cancer	0.00132	0.00606	CcSEcCtD
Phenazopyridine—SCN8A—Developmental Biology—CDK4—urinary bladder cancer	0.00129	0.00295	CbGpPWpGaD
Phenazopyridine—SCN7A—Axon guidance—SRC—urinary bladder cancer	0.00129	0.00293	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—PPARG—urinary bladder cancer	0.00129	0.00293	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—NCOR1—urinary bladder cancer	0.00127	0.00289	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—RHOA—urinary bladder cancer	0.00125	0.00286	CbGpPWpGaD
Phenazopyridine—SCN11A—Axon guidance—MMP9—urinary bladder cancer	0.00124	0.00284	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—CREBBP—urinary bladder cancer	0.00124	0.00282	CbGpPWpGaD
Phenazopyridine—SCN5A—L1CAM interactions—EGFR—urinary bladder cancer	0.00123	0.00279	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—NCOR1—urinary bladder cancer	0.00122	0.00278	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—NCOR1—urinary bladder cancer	0.00122	0.00278	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—NCOR1—urinary bladder cancer	0.00118	0.00268	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—PPARG—urinary bladder cancer	0.00118	0.00268	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—NCOR1—urinary bladder cancer	0.00118	0.00268	CbGpPWpGaD
Phenazopyridine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00117	0.00538	CcSEcCtD
Phenazopyridine—SCN7A—Developmental Biology—ERBB2—urinary bladder cancer	0.00116	0.00265	CbGpPWpGaD
Phenazopyridine—SCN9A—Axon guidance—RHOA—urinary bladder cancer	0.00116	0.00264	CbGpPWpGaD
Phenazopyridine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00115	0.00527	CcSEcCtD
Phenazopyridine—SCN11A—Axon guidance—SRC—urinary bladder cancer	0.00115	0.00261	CbGpPWpGaD
Phenazopyridine—SCN8A—Axon guidance—MMP9—urinary bladder cancer	0.00114	0.00259	CbGpPWpGaD
Phenazopyridine—SCN5A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.00114	0.00259	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—CREBBP—urinary bladder cancer	0.00113	0.00258	CbGpPWpGaD
Phenazopyridine—SCN7A—Axon guidance—EGFR—urinary bladder cancer	0.00113	0.00257	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—RHOA—urinary bladder cancer	0.00112	0.00255	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—RHOA—urinary bladder cancer	0.00111	0.00253	CbGpPWpGaD
Phenazopyridine—Dyspepsia—Epirubicin—urinary bladder cancer	0.00109	0.00503	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00107	0.00494	CcSEcCtD
Phenazopyridine—SCN9A—Axon guidance—ERBB2—urinary bladder cancer	0.00107	0.00245	CbGpPWpGaD
Phenazopyridine—SCN7A—Axon guidance—KRAS—urinary bladder cancer	0.00107	0.00243	CbGpPWpGaD
Phenazopyridine—SCN4A—Axon guidance—RHOA—urinary bladder cancer	0.00106	0.00243	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—RHOA—urinary bladder cancer	0.00106	0.00243	CbGpPWpGaD
Phenazopyridine—SCN8A—Axon guidance—SRC—urinary bladder cancer	0.00105	0.00239	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—CDK4—urinary bladder cancer	0.00105	0.00239	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—ERBB2—urinary bladder cancer	0.00103	0.00236	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—RHOA—urinary bladder cancer	0.00103	0.00234	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—RHOA—urinary bladder cancer	0.00103	0.00234	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—ERBB2—urinary bladder cancer	0.00103	0.00234	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—RHOA—urinary bladder cancer	0.00102	0.00233	CbGpPWpGaD
Phenazopyridine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00101	0.00466	CcSEcCtD
Phenazopyridine—SCN11A—Axon guidance—EGFR—urinary bladder cancer	0.001	0.00229	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—CDK4—urinary bladder cancer	0.001	0.00228	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—MMP9—urinary bladder cancer	0.000996	0.00227	CbGpPWpGaD
Phenazopyridine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000994	0.00457	CcSEcCtD
Phenazopyridine—SCN4A—Axon guidance—ERBB2—urinary bladder cancer	0.000986	0.00225	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—ERBB2—urinary bladder cancer	0.000986	0.00225	CbGpPWpGaD
Phenazopyridine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000979	0.0045	CcSEcCtD
Phenazopyridine—SCN5A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000975	0.00222	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—CDK4—urinary bladder cancer	0.000962	0.00219	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—CDK4—urinary bladder cancer	0.000962	0.00219	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—PPARG—urinary bladder cancer	0.000951	0.00217	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—ERBB2—urinary bladder cancer	0.00095	0.00217	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—ERBB2—urinary bladder cancer	0.00095	0.00217	CbGpPWpGaD
Phenazopyridine—SCN11A—Axon guidance—KRAS—urinary bladder cancer	0.000949	0.00216	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—ERBB2—urinary bladder cancer	0.000946	0.00216	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—EP300—urinary bladder cancer	0.000944	0.00215	CbGpPWpGaD
Phenazopyridine—Pruritus—Methotrexate—urinary bladder cancer	0.00094	0.00432	CcSEcCtD
Phenazopyridine—SCN1A—Developmental Biology—CDK4—urinary bladder cancer	0.000928	0.00212	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—CDK4—urinary bladder cancer	0.000928	0.00212	CbGpPWpGaD
Phenazopyridine—SCN9A—Axon guidance—MMP9—urinary bladder cancer	0.00092	0.0021	CbGpPWpGaD
Phenazopyridine—SCN8A—Axon guidance—EGFR—urinary bladder cancer	0.000919	0.0021	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—SRC—urinary bladder cancer	0.000918	0.00209	CbGpPWpGaD
Phenazopyridine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000916	0.00421	CcSEcCtD
Phenazopyridine—SCN9A—Developmental Biology—CREBBP—urinary bladder cancer	0.000914	0.00208	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—PPARG—urinary bladder cancer	0.00091	0.00207	CbGpPWpGaD
Phenazopyridine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000909	0.00418	CcSEcCtD
Phenazopyridine—SCN7A—Axon guidance—HRAS—urinary bladder cancer	0.000905	0.00206	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—MMP9—urinary bladder cancer	0.000887	0.00202	CbGpPWpGaD
Phenazopyridine—Pruritus—Epirubicin—urinary bladder cancer	0.00088	0.00405	CcSEcCtD
Phenazopyridine—SCN3A—Axon guidance—MMP9—urinary bladder cancer	0.00088	0.00201	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—PPARG—urinary bladder cancer	0.000874	0.00199	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—PPARG—urinary bladder cancer	0.000874	0.00199	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—CREBBP—urinary bladder cancer	0.000874	0.00199	CbGpPWpGaD
Phenazopyridine—SCN8A—Axon guidance—KRAS—urinary bladder cancer	0.000868	0.00198	CbGpPWpGaD
Phenazopyridine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000851	0.00391	CcSEcCtD
Phenazopyridine—SCN9A—Axon guidance—SRC—urinary bladder cancer	0.000848	0.00193	CbGpPWpGaD
Phenazopyridine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000848	0.0039	CcSEcCtD
Phenazopyridine—SCN4A—Axon guidance—MMP9—urinary bladder cancer	0.000845	0.00193	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—MMP9—urinary bladder cancer	0.000845	0.00193	CbGpPWpGaD
Phenazopyridine—Vomiting—Methotrexate—urinary bladder cancer	0.000845	0.00388	CcSEcCtD
Phenazopyridine—SCN1A—Developmental Biology—PPARG—urinary bladder cancer	0.000843	0.00192	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—PPARG—urinary bladder cancer	0.000843	0.00192	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—EP300—urinary bladder cancer	0.000841	0.00192	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—CREBBP—urinary bladder cancer	0.00084	0.00191	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—CREBBP—urinary bladder cancer	0.00084	0.00191	CbGpPWpGaD
Phenazopyridine—Rash—Methotrexate—urinary bladder cancer	0.000838	0.00385	CcSEcCtD
Phenazopyridine—Dermatitis—Methotrexate—urinary bladder cancer	0.000837	0.00385	CcSEcCtD
Phenazopyridine—Headache—Methotrexate—urinary bladder cancer	0.000833	0.00383	CcSEcCtD
Phenazopyridine—SCN5A—Developmental Biology—NCOR1—urinary bladder cancer	0.000827	0.00189	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—RHOA—urinary bladder cancer	0.000827	0.00188	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—SRC—urinary bladder cancer	0.000818	0.00187	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—MMP9—urinary bladder cancer	0.000815	0.00186	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—MMP9—urinary bladder cancer	0.000815	0.00186	CbGpPWpGaD
Phenazopyridine—Pruritus—Doxorubicin—urinary bladder cancer	0.000814	0.00374	CcSEcCtD
Phenazopyridine—SCN8A—Developmental Biology—MMP9—urinary bladder cancer	0.000812	0.00185	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—SRC—urinary bladder cancer	0.000811	0.00185	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—CREBBP—urinary bladder cancer	0.00081	0.00185	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—CREBBP—urinary bladder cancer	0.00081	0.00185	CbGpPWpGaD
Phenazopyridine—SCN11A—Axon guidance—HRAS—urinary bladder cancer	0.000807	0.00184	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—EGFR—urinary bladder cancer	0.000805	0.00183	CbGpPWpGaD
Phenazopyridine—SCN5A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000791	0.0018	CbGpPWpGaD
Phenazopyridine—Vomiting—Epirubicin—urinary bladder cancer	0.000791	0.00364	CcSEcCtD
Phenazopyridine—SCN3A—Developmental Biology—RHOA—urinary bladder cancer	0.000791	0.0018	CbGpPWpGaD
Phenazopyridine—Nausea—Methotrexate—urinary bladder cancer	0.000789	0.00363	CcSEcCtD
Phenazopyridine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000787	0.00362	CcSEcCtD
Phenazopyridine—Rash—Epirubicin—urinary bladder cancer	0.000784	0.00361	CcSEcCtD
Phenazopyridine—Dermatitis—Epirubicin—urinary bladder cancer	0.000784	0.0036	CcSEcCtD
Phenazopyridine—SCN4A—Axon guidance—SRC—urinary bladder cancer	0.000779	0.00178	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—SRC—urinary bladder cancer	0.000779	0.00178	CbGpPWpGaD
Phenazopyridine—Headache—Epirubicin—urinary bladder cancer	0.000779	0.00358	CcSEcCtD
Phenazopyridine—SCN8A—Developmental Biology—EP300—urinary bladder cancer	0.00077	0.00175	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—TNF—urinary bladder cancer	0.000766	0.00175	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—ERBB2—urinary bladder cancer	0.000765	0.00174	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—KRAS—urinary bladder cancer	0.00076	0.00173	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—RHOA—urinary bladder cancer	0.00076	0.00173	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—RHOA—urinary bladder cancer	0.00076	0.00173	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—SRC—urinary bladder cancer	0.000752	0.00171	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—SRC—urinary bladder cancer	0.000752	0.00171	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—SRC—urinary bladder cancer	0.000748	0.00171	CbGpPWpGaD
Phenazopyridine—SCN9A—Axon guidance—EGFR—urinary bladder cancer	0.000743	0.00169	CbGpPWpGaD
Phenazopyridine—Nausea—Epirubicin—urinary bladder cancer	0.000739	0.0034	CcSEcCtD
Phenazopyridine—SCN8A—Axon guidance—HRAS—urinary bladder cancer	0.000738	0.00168	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—RHOA—urinary bladder cancer	0.000733	0.00167	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—RHOA—urinary bladder cancer	0.000733	0.00167	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—ERBB2—urinary bladder cancer	0.000732	0.00167	CbGpPWpGaD
Phenazopyridine—Vomiting—Doxorubicin—urinary bladder cancer	0.000732	0.00336	CcSEcCtD
Phenazopyridine—Rash—Doxorubicin—urinary bladder cancer	0.000726	0.00334	CcSEcCtD
Phenazopyridine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000725	0.00333	CcSEcCtD
Phenazopyridine—SCN5A—Axon guidance—RHOA—urinary bladder cancer	0.000722	0.00165	CbGpPWpGaD
Phenazopyridine—Headache—Doxorubicin—urinary bladder cancer	0.000721	0.00331	CcSEcCtD
Phenazopyridine—SCN11A—Developmental Biology—EGFR—urinary bladder cancer	0.000717	0.00164	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—EGFR—urinary bladder cancer	0.000711	0.00162	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—ERBB2—urinary bladder cancer	0.000703	0.0016	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—ERBB2—urinary bladder cancer	0.000703	0.0016	CbGpPWpGaD
Phenazopyridine—SCN9A—Axon guidance—KRAS—urinary bladder cancer	0.000702	0.0016	CbGpPWpGaD
Phenazopyridine—Nausea—Doxorubicin—urinary bladder cancer	0.000684	0.00314	CcSEcCtD
Phenazopyridine—SCN4A—Axon guidance—EGFR—urinary bladder cancer	0.000683	0.00156	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—EGFR—urinary bladder cancer	0.000683	0.00156	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—TNF—urinary bladder cancer	0.000683	0.00156	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—ERBB2—urinary bladder cancer	0.000678	0.00155	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—ERBB2—urinary bladder cancer	0.000678	0.00155	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—KRAS—urinary bladder cancer	0.000677	0.00154	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—KRAS—urinary bladder cancer	0.000672	0.00153	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—ERBB2—urinary bladder cancer	0.000668	0.00152	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—EGFR—urinary bladder cancer	0.000659	0.0015	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—EGFR—urinary bladder cancer	0.000659	0.0015	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—MMP9—urinary bladder cancer	0.000656	0.0015	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—EGFR—urinary bladder cancer	0.000656	0.0015	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—CDK4—urinary bladder cancer	0.000652	0.00149	CbGpPWpGaD
Phenazopyridine—SCN7A—Developmental Biology—HRAS—urinary bladder cancer	0.000646	0.00147	CbGpPWpGaD
Phenazopyridine—SCN4A—Axon guidance—KRAS—urinary bladder cancer	0.000645	0.00147	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—KRAS—urinary bladder cancer	0.000645	0.00147	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—MMP9—urinary bladder cancer	0.000628	0.00143	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—TNF—urinary bladder cancer	0.000625	0.00142	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—EP300—urinary bladder cancer	0.000622	0.00142	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—KRAS—urinary bladder cancer	0.000622	0.00142	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—KRAS—urinary bladder cancer	0.000622	0.00142	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—KRAS—urinary bladder cancer	0.00062	0.00141	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—SRC—urinary bladder cancer	0.000605	0.00138	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—MMP9—urinary bladder cancer	0.000603	0.00138	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—MMP9—urinary bladder cancer	0.000603	0.00138	CbGpPWpGaD
Phenazopyridine—SCN9A—Axon guidance—HRAS—urinary bladder cancer	0.000597	0.00136	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—EP300—urinary bladder cancer	0.000595	0.00136	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—PPARG—urinary bladder cancer	0.000593	0.00135	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—MMP9—urinary bladder cancer	0.000582	0.00133	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—MMP9—urinary bladder cancer	0.000582	0.00133	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—SRC—urinary bladder cancer	0.000579	0.00132	CbGpPWpGaD
Phenazopyridine—SCN11A—Developmental Biology—HRAS—urinary bladder cancer	0.000576	0.00131	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—MMP9—urinary bladder cancer	0.000573	0.00131	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—EP300—urinary bladder cancer	0.000572	0.0013	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—EP300—urinary bladder cancer	0.000572	0.0013	CbGpPWpGaD
Phenazopyridine—SCN3A—Axon guidance—HRAS—urinary bladder cancer	0.000571	0.0013	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—CREBBP—urinary bladder cancer	0.000569	0.0013	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—SRC—urinary bladder cancer	0.000556	0.00127	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—SRC—urinary bladder cancer	0.000556	0.00127	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—EP300—urinary bladder cancer	0.000552	0.00126	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—EP300—urinary bladder cancer	0.000552	0.00126	CbGpPWpGaD
Phenazopyridine—SCN4A—Axon guidance—HRAS—urinary bladder cancer	0.000549	0.00125	CbGpPWpGaD
Phenazopyridine—SCN2A—Axon guidance—HRAS—urinary bladder cancer	0.000549	0.00125	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—SRC—urinary bladder cancer	0.000536	0.00122	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—SRC—urinary bladder cancer	0.000536	0.00122	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—EGFR—urinary bladder cancer	0.00053	0.00121	CbGpPWpGaD
Phenazopyridine—SCN1A—Axon guidance—HRAS—urinary bladder cancer	0.000529	0.00121	CbGpPWpGaD
Phenazopyridine—SCN10A—Axon guidance—HRAS—urinary bladder cancer	0.000529	0.00121	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—SRC—urinary bladder cancer	0.000528	0.0012	CbGpPWpGaD
Phenazopyridine—SCN8A—Developmental Biology—HRAS—urinary bladder cancer	0.000527	0.0012	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	0.000515	0.00117	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—EGFR—urinary bladder cancer	0.000507	0.00116	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—TNF—urinary bladder cancer	0.000505	0.00115	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—KRAS—urinary bladder cancer	0.000501	0.00114	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—EGFR—urinary bladder cancer	0.000487	0.00111	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—EGFR—urinary bladder cancer	0.000487	0.00111	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—TNF—urinary bladder cancer	0.000483	0.0011	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—KRAS—urinary bladder cancer	0.000479	0.00109	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	0.000477	0.00109	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—EGFR—urinary bladder cancer	0.00047	0.00107	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—EGFR—urinary bladder cancer	0.00047	0.00107	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—TNF—urinary bladder cancer	0.000464	0.00106	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—TNF—urinary bladder cancer	0.000464	0.00106	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—EGFR—urinary bladder cancer	0.000463	0.00106	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—KRAS—urinary bladder cancer	0.000461	0.00105	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—KRAS—urinary bladder cancer	0.000461	0.00105	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—TNF—urinary bladder cancer	0.000448	0.00102	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—TNF—urinary bladder cancer	0.000448	0.00102	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—KRAS—urinary bladder cancer	0.000444	0.00101	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—KRAS—urinary bladder cancer	0.000444	0.00101	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—KRAS—urinary bladder cancer	0.000437	0.000997	CbGpPWpGaD
Phenazopyridine—SCN9A—Developmental Biology—HRAS—urinary bladder cancer	0.000426	0.000971	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	0.000409	0.000932	CbGpPWpGaD
Phenazopyridine—SCN3A—Developmental Biology—HRAS—urinary bladder cancer	0.000407	0.000929	CbGpPWpGaD
Phenazopyridine—SCN2A—Developmental Biology—HRAS—urinary bladder cancer	0.000391	0.000892	CbGpPWpGaD
Phenazopyridine—SCN4A—Developmental Biology—HRAS—urinary bladder cancer	0.000391	0.000892	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—EP300—urinary bladder cancer	0.000388	0.000884	CbGpPWpGaD
Phenazopyridine—SCN1A—Developmental Biology—HRAS—urinary bladder cancer	0.000377	0.000861	CbGpPWpGaD
Phenazopyridine—SCN10A—Developmental Biology—HRAS—urinary bladder cancer	0.000377	0.000861	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—SRC—urinary bladder cancer	0.000377	0.00086	CbGpPWpGaD
Phenazopyridine—SCN5A—Axon guidance—HRAS—urinary bladder cancer	0.000372	0.000848	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	0.00033	0.000753	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—TNF—urinary bladder cancer	0.000315	0.000718	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	0.000312	0.000712	CbGpPWpGaD
Phenazopyridine—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	0.000265	0.000605	CbGpPWpGaD
